Regenicin Current Valuation vs. Debt To Equity
Considering Regenicin's profitability and operating efficiency indicators, Regenicin may not be well positioned to generate adequate gross income at this time. It has a very high probability of underperforming in December. Profitability indicators assess Regenicin's ability to earn profits and add value for shareholders.
Check out Your Equity Center.
For Regenicin profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Regenicin to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Regenicin utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Regenicin's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Regenicin over time as well as its relative position and ranking within its peers.
Regenicin |
Regenicin Debt To Equity vs. Current Valuation Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Regenicin's current stock value. Our valuation model uses many indicators to compare Regenicin value to that of its competitors to determine the firm's financial worth. Regenicin is currently regarded number one company in current valuation category among its peers. It also is currently regarded as top stock in debt to equity category among its peers . The ratio of Current Valuation to Debt To Equity for Regenicin is about 1,938,988 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Regenicin by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Regenicin's Pink Sheet. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued.Regenicin Current Valuation vs. Competition
Regenicin is currently regarded number one company in current valuation category among its peers. After adjusting for long-term liabilities, total market size of Biotechnology industry is at this time estimated at about 23.44 Billion. Regenicin adds roughly 659,256 in current valuation claiming only tiny portion of stocks in Biotechnology industry.
Regenicin Debt To Equity vs. Current Valuation
Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Regenicin |
| = | 659.26 K |
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
Debt to Equity is calculated by dividing the Total Debt of a company by its Equity. If the debt exceeds equity of a company, then the creditors have more stakes in a firm than the stockholders. In other words, Debt to Equity ratio provides analysts with insights about composition of both equity and debt, and its influence on the valuation of the company.
Regenicin |
| = | 0.34 % |
High Debt to Equity ratio typically indicates that a firm has been borrowing aggressively to finance its growth and as a result may experience a burden of additional interest expense. This may reduce earnings or future growth. On the other hand a small D/E ratio may indicate that a company is not taking enough advantage from financial leverage. Debt to Equity ratio measures how the company is leveraging borrowing against the capital invested by the owners.
Regenicin Debt To Equity Comparison
Regenicin is currently under evaluation in debt to equity category among its peers.
Regenicin Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Regenicin, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Regenicin will eventually generate negative long term returns. The profitability progress is the general direction of Regenicin's change in net profit over the period of time. It can combine multiple indicators of Regenicin, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
Regenicin, Inc. focuses on developing and commercializing a technology of tissue-engineered skin substitutes. Regenicin, Inc. was incorporated in 2007 and is headquartered in Little Falls, New Jersey. Regenicin operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 3 people.
Regenicin Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Regenicin. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Regenicin position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Regenicin's important profitability drivers and their relationship over time.
Use Regenicin in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Regenicin position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Regenicin will appreciate offsetting losses from the drop in the long position's value.Regenicin Pair Trading
Regenicin Pair Trading Analysis
The ability to find closely correlated positions to Regenicin could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Regenicin when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Regenicin - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Regenicin to buy it.
The correlation of Regenicin is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Regenicin moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Regenicin moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Regenicin can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Regenicin position
In addition to having Regenicin in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Construction Thematic Idea Now
Construction
Fama and French investing themes focus on testing asset pricing under different economic assumptions. The Construction theme has 61 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Construction Theme or any other thematic opportunities.
| View All Next | Launch |
Other Information on Investing in Regenicin Pink Sheet
To fully project Regenicin's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Regenicin at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Regenicin's income statement, its balance sheet, and the statement of cash flows.